John Shields
Advisor, Science and Technology @ Abingworth
John Shields is a Series A investor at Abingworth focused on Therapeutics and Biotechnology. John has 13 years of operational experience in life science companies. He joined Abingworth in 2001 from Cantab Pharmaceuticals where he was Senior Vice President, Research. He had a strong role in business development and played a significant part in the in-licensing of new products and technologies to the firm. Prior to Cantab, he was at theGlaxo Institute for Molecular Biology in Geneva, Switzerland. From 1982 to 1988, he held research positions at the Institute of Child Health, the University of London, UK. John has a PhD in Immunology from the University of Glasgow. He has published more than 30 papers in peer-reviewed journals including Science. At Abingworth, John is involved with scientific evaluation of new and existing investments and works closely with UK universities and early-stage companies.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries John Shields invests in
Stages John Shields invests in
Countries John Shields invests in
Investment Focus
Industry
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VirionHealth
|
VirionHealth is a biotechnology company developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology will provide a new class of biological antiviral active across a range of infectious diseases. | $17M / Series A / Oct 12, 2017 |
About Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
Abingworth Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Gallagher
Partner
|
|||
|
John Shields
Advisor, Science and Technology
|
|||
Quentin Lloyd-Harris
Partner
|
|||
Alex Asquith
General Counsel and Chief Financial Officer
|
|||
Andrew Sinclair
Partner & Portfolio Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does John Shields invest in?
John Shields invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did John Shields last invest?
The most recent investment recorded for John Shields closed in Oct 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
